Patients younger than 50 years diagnosed with EOCRC were more likely to have a benign colon indication, bleeding, and family history of CRC.

The phase 3 NRG Oncology GU005 trial of SBRT vs MH-IMRT for intermediate-risk prostate cancer had co-primary endpoints including disease control and patient-reported outcomes.

An investigator presented results from a pre-specified primary efficacy analysis of the phase 2 EXTEND trial testing the progression-free survival (PFS) benefits of metastasis-directed therapy by ...

Researchers sought to determine whether zanubrutinib would outperform acalabrutinib in an indirect treatment comparison in R/R CLL.

Researchers review melanoma subtypes, focusing on therapeutic advances in metastatic ocular melanoma, including TILs, ImmTACs, and targeted therapies.

Subgroup analyses showed this PFS advantage was consistent across patient subgroups and alpha‐fetoprotein levels.

In breast cancer patients with a high recurrence score, the 5-year disease-free rate was significantly higher for patients receiving taxanes with anthracycline and cyclophosphamide than for those ...

GO-PIMs are prevalent in patients with cancer treated in a national health care system, with increasing GO-PIMs independently linked to frailty and worse clinical outcomes,” the researchers wrote.

Enhanced staffing and flexible resource allocation were key in managing patient surge after Oct. 7, 2023, attack in Southern Israel.

Effective coordination among multidisciplinary team and individualized management strategies has emerged as a cornerstone of optimal NET care.

Researchers present an overview of treatment and management strategies for patients with HR+/HER2+ breast cancer, including common adverse effects.

A MyChart-driven data collection strategy proved acceptable, appropriate, and feasible for gathering SOGI information from patients at a cancer center in the South,” the researchers wrote.